YKL-40 in the diagnosis, prediction of prognosis, and platinum sensitivity in serous epithelial ovarian cancer

Abstract

Objective: To evaluate the use of YKL-40 in the discrimination between benign and malignant adnexal mass and to determine its prognostic value in assessing residual tumor after primary cytoreduction and platinum sensitivity in serous epithelial ovarian carcinoma (EOC).

Materials and Methods: During the three years from January 2015 to December 2017, a nonconsecutive series of 100 patients (60 malignant, 40 benign) who underwent surgery for an adnexal mass were enrolled in the study. Preoperatively, serum samples were collected for YKL-40 level analysis.

Results: YKL-40 (receiver operator characteristics (ROC)-area under curve (AUC)=0.83) was a significantly better predictor of EOC than cancer antigen-125 (ROC-AUC=0.75). Using a cut-off for YKL-40 of 47.7 ng/mL had a sensitivity of 80% and a specificity of 70%. Higher serum YKL-40 levels were associated with advanced stage, higher grade, residual tumor after primary cytoreduction and recurrence. Platinum-sensitive patients had significantly elevated levels of YKL-40 compared with platinum-resistant or refractory patients.

Conclusion: The results obtained from our study support the use of serum YKL-40 for the discrimination between malignant and benign ovarian tumors YKL-40 levels in patients with serous EOC may also predict disease residual disease after primary cytoreduction and recurrence. Further studies are needed to understand the relationship between YKL-40 and platinum sensitivity.

Keywords: YKL-40, ovarian cancer, biomarker, platinum sensitivity

YKL-40 in the management of adnexal masses and may predict residual disease after primary cytoreduction and recurrence.
Introduction

Ovarian cancer is a common gynecologic malignancy associated with poor prognosis worldwide. Patients with early stage ovarian cancer have a 5-year overall survival of 70-90%. However, more than 70% of women are diagnosed as having stage III or IV disease, which has a 5-year survival rate of around only 25%(1). This poor prognosis emphasizes the need for early detection in screening programs and prognostic markers to guide individual cancer treatment. The standard treatment of early epithelial ovarian carcinoma (EOC) is full staging including pelvic and paraaortic lymphadenectomy. Debulking surgery followed by platinum-based chemotherapy is the cornerstone of treatment of advanced EOC(2). Neoadjuvant chemotherapy followed by interval cytoreduction has been a debatable alternative option. A metaanalysis of 21 non-randomized trials concluded that survival between two groups was similar(3). Subsequently, Vergote et al. performed a randomized trial including patients with stage IIIC-IV EOC and found that optimal cytoreduction was higher in an interval cytoreduction group compared with a primary cytoreduction group with significantly less morbidity in the interval cytoreduction group. However, a number of studies showed that leaving no residual tumor following primary debulking surgery was the single most important independent prognostic factor in advanced EOC(4,5). Patients who are at higher risk of residual tumor after primary cytoreduction should be isolated in the preoperative period, and these should benefit from neoadjuvant chemotherapy. A glycoprotein, YKL-40, also known as chitinase-3-like 1 protein, was identified in the 1990s. Since then, it has been of special interest because it is associated with degradation of extracellular matrix and promotes angiogenesis in a vascular endothelial growth factor (VEGF)-independent manner(6-7). During the last decade, YKL-40 has been increasingly studied in several tumor types(6,8-10). In vitro, YKL-40 upregulates VEGF and is associated with tumor angiogenesis(6). In vivo animal studies demonstrated that inhibition of YKL-40 decreased angiogenesis, tumor formation, and metastasis(11-13). Recent studies showed that neutrophils and tumour cells expressed and released YKL-40 into the blood(8,14). Increased serum levels of YKL-40 were shown in some cancer types such as breast cancer, lung cancer, colorectal cancer, melanoma, and endometrial cancer(6,7,10,13,15). YKL-40 was suggested to have the potential to be a better marker than cancer antigen-125 (CA-125) for early diagnosis of EOC(17,18). However, results from recent studies on the diagnostic efficiency of YKL-40 were inconsistent(18-20). There are a limited number of studies reporting that elevated plasma YKL-40 levels are associated with worse outcomes in patients with ovarian cancer for serum YKL-40(6). In this study, we aimed to evaluate the usefulness of YKL-40 in the discrimination of benign and malignant adnexal masses and to determine the efficacy of YKL-40 in the preoperative estimation of the prognostic parameters such as stage and grade of the disease, residual tumor after primary cytoreduction, and response to platinum-based chemotherapy.

Materials and Methods

This prospective observational study was conducted at Istanbul University Cerrahpasa Faculty of Medicine, Division of Gynecologic Oncology, between January 2015 and December 2017. The study was approved by the Ethics Committee of Istanbul University Cerrahpasa Faculty of Medicine (protocol number: 83045809-604.01.02). Written informed consent was obtained from all patients. The manuscript was prepared in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology statement(24). Blood samples were collected preoperatively from a nonconsecutive series of 100 patients who were planned to undergo surgery for an adnexal mass in our clinic. Exclusion criteria were the presence of one or more of the following: i) a suspicious malignancy other than ovarian cancer; ii) systematic disease including renal and/or hepatic impairment; iii) neoadjuvant chemotherapy; iv) history of any malignancy; v) ovarian malignancy other than serous histopathology; and vi) pregnancy. Frozen section evaluation was performed intraoperatively in the presence of suspicion in the diagnosis. The same gynecologic pathologists evaluated all of the specimens. The stage of disease and histologic types were in accordance with the International Federation of Gynecology and Obstetrics classification(25). Maximal cytoreduction was defined as removing all gross tumoral tissue with no visible disease left. Optimal cytoreduction was defined as residual volume of 1 cm or less after surgery. Residual tumor more than 1 cm was classified as suboptimal cytoreduction. All patients with serous EOC (except those with stage IA and IB disease) received 6 cycles of adjuvant carboplatinum and paclitaxel. The platinum-free interval was defined as the interval from the last treatment with platinum to recurrence. Patients were accepted as platinum sensitive, if the platinum-free interval was longer than 6 months; platinum resistant, if it was shorter than 6 months; or platinum refractory, if the disease was persistent or progressive during the first-line chemotherapy. Progression of disease was diagnosed in the presence of elevated CA-125 and imaging results according to Response Evaluation Criteria in Solid Tumors criteria(26). Progression-free survival was defined as the time interval between primary surgery and progression or death from any cause. Blood samples were collected in EDTA-containing tubes and anticoagulant-free tubes after an overnight fast on the morning before the surgery. Plasma and serum were separated immediately and stored at -80 °C until analysis. After reaching the desired number of cases in both groups, all serum samples were defrosted at room temperature in the medical biochemistry laboratory of the faculty. Serum
YKL-40 concentrations were determined by a commercial enzyme-linked immunosorbent (ELISA) kit using a double-antibody sandwich enzyme immunoassay technique (human chitinase-3-like protein 1 YKL-40, ELISA Kit, Cat. No. YHB0684Hu; Shanghai Yehua Biological Technology Co. Ltd, China). Each ELISA analysis was performed according to the manufacturer’s instructions. All tests showed intraassay and interassay coefficients of variations below 6% (n=10) and 7.5% (n=10), respectively. The analytical sensitivity of the test was 0.52 ng/mL.

**Statistical Analysis**

Patients’ characteristics and clinical features were summarized using standard descriptive statistics. Mann-Whitney U test was used for comparison between two groups. T-test was used in comparison of independent samples’ average. Receiver operating characteristics curves (ROC) were constructed for YKL-40 and CA-125 serum concentrations as diagnostics for cancer by plotting sensitivity versus 1-specificity, and area under curve (AUC) was calculated for both markers. All p-values were two sided and p<0.05 were considered as statistically significant. Statistical analyses were performed using SPSS version 21.

**Results**

Age, BMI, and menopausal status were similar between the malignant and benign groups (Table 1). The pathologic subtypes of benign ovarian tumors included endometriotic cysts (n=14), serous cystadenoma (n=12), dermoid cyst (n=9), and mucinous cystadenoma (n=5). Serum YKL-40 and CA-125 levels were significantly higher in patients with serous EOC, but CA-19-9 and CA-15-3 levels did not differ between the groups.

As illustrated in Figure 1, sensitivity was 80% and specificity was 70%, respectively, when a cut-off serum YKL-40 level of 47.7 ng/mL was applied. When 34.3 ng/mL was used as a cut-off value, the specificity decreased to 58.5%; however, sensitivity increased to 90%. The obtained areas under the ROC curves for YKL-40 and CA-125 were significantly elevated levels in the latter patients (Table 2). When patients who had recurrence were investiagted in terms of platinum sensitivity, it was found that YKL-40 were significantly higher in the sensitive group compared with resistant and refractory groups (mean values of YKL-40: 179.2, 146.9 and 141.7 in platinum-sensitive, resistant, and refractory patients, respectively) (Figure 2).

| Table 1. Clinical and laboratory characteristics of groups with malignant and benign disease |
|------------------------------------------------------|-----------------|-----------------|
| **Malignant group** (n=60) | **Benign group** (n=40) | p |
| Mean | Mean | |
| **Age (years)** | 55.1 | 49.7 | NS |
| **BMI (kg/m²)** | 26.6 | 27.1 | NS |
| **Menopausal status** n (%) | n (%) | n (%) |
| Premenopausal | 19 (31.6) | 14 (35) |
| Postmenopausal | 41 (68.3) | 26 (65) |
| **YKL-40 (ng/mL)** | 102.9 | 43.9 | <0.05 |
| **CA-125 (U/mL)** | 1137.5 | 151.9 | <0.05 |
| **CA 19-9 (U/mL)** | 56.5 | 33.6 | NS |
| **CA 15-3 (U/mL)** | 72.5 | 18.5 | NS |

NS: Not significant, CA: Cancer antigen, BMI: Body mass index

| Table 2. Clinical characteristics and plasma YKL-40 levels of patients with serous epithelial ovarian carcinoma |
|------------------------------------------------------|-----------------|-----------------|
| **Histology** | n (%) | **YKL-40 (ng/mL)** Mean ± SD | p |
| Serous | 60 (100) | 102.9±63.5 | - |
| FIGO stage | | | 0.001 |
| IA-IC | 15 (25) | 50.6±23.6 | |
| II | 4 (6.6) | 107.2±63.5 | |
| IIA-IIIC2 | 41 (68.3) | 121.7±63.7 | |
| Histologic grade | | | 0.002 |
| 1 | 8 (13.3) | 34.6±16.4 | |
| 2 | 5 (8.3) | 156.6±133.7 | |
| 3 | 50 (83.3) | 111.7±59.1 | |
| Residual tumor | | | <0.001 |
| 0 | 51 (85) | 94.1±57.4 | |
| ≤1 cm | 7 (11.6) | 136.8±38.3 | |
| >1 cm | 3 (3.3) | 261.2±14.1 | |
| Recurrence | | | <0.001 |
| No | 42 (70) | 77.4±47.5 | |
| Yes | 18 (30) | 162.5±56.5 | |

SD: Standard deviation, FIGO: International Federation of Gynecology and Obstetrics
Discussion

There are still limited data investigating serum markers to differentiate between benign ovarian tumors and epithelial ovarian carcinoma.

ROC: Receiver operating characteristic, CA-125: Cancer antigen-125, AUC: Area under curve

Study Limitations

It has been suggested that future studies of serum YKL-40 should be powered to investigate its value as a biomarker in individual histologic subtypes of ovarian cancer. In our study, all patients with ovarian malignancy had the same histopathology. The present study included patients over a period of almost three years. However, because of the short study period, the same practices (same surgical team, same chemotherapy regimen starting on almost same postoperative days) were applied to all patients. The limitations of this study include the small number of patients, which means that strong conclusions cannot be drawn.

Conclusion

In conclusion, our findings suggest that preoperative serum YKL-40 can be used for to discriminate between malignant and benign ovarian tumors. In addition, higher YKL-40 levels indicate a higher risk of recurrence. Conflicting results regarding YKL-40 and platinum sensitivity should be eliminated by larger prospective studies.
Ethics

Ethics Committee Approval: The study was approved by the Ethics Committee of Istanbul University Cerrahpaşa Faculty of Medicine (protocol number: 83045809-604.01.02).

Informed Consent: Consent form was filled out by all participants.

Peer-review: Externally peer-reviewed.

Authorship Contributions

Surgical and Medical Practices: İ.K., N.T., VŞ., H.T., M.A., FD., T.B., Concept: İ.K., N.T., T.B., FD, H.U., Design: İ.K., N.T., T.B., VŞ., H.U., Data Collection or Processing: N.T., H.T., G Ş., R.G., H.U., Analysis or Interpretation: H.U., İ.K., G Ş., H.U., Literature Search: İ.K., VŞ., H.T., H.U., Writing: İ.K., H.T.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29.
2. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248-59.
3. Kang S, Nam BH. Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies. Ann Surg Oncol 2009;16:2315-20.
4. Verrone I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363:943-53.
5. Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer: N Engl J Med 2010;363:943-53.
6. Boisen MK, Madsen CV, Dehlendorff C, Jakobsen A, Johansen JS, Steffensen KD. The prognostic value of plasma YKL-40 in patients with chemotherapy-resistant ovarian cancer treated with bevacizumab. Int J Gynecol Cancer 2016;26:1390-8.
7. Kotowicz B, Fuksewicz M, Jonska Gmyrek J, Wagrodzki M, Kowalska M. Preoperative serum levels of YKL-40 and CA 125 as a prognostic indicators in patients with endometrial cancer. Eur J Obstet Gynecol Reprod Biol 2017;215:141-7.
8. Ilmar D, Ozturk B, Coskun U, Tekin E, Sancak B, Yildiz R, et al. Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer. Adv Ther 2008;25:801-9.
9. Shao R. YKL-40 acts as an angiogenic factor to promote tumor angiogenesis. Front Physiol 2013;4:122.
10. Johansen JS, Christensen IJ, Jergensen LN, Olsen J, Rahr HB, Nielsen KT, et al. Serum YKL-40 in risk assessment for colorectal cancer: a prospective study of 4,406 subjects at risk of colorectal cancer. Cancer Epidemiol Biomark Prev 2015;24:621-6.
11. Shao R, Hamel K, Petersen L, Cao QJ, Arenas RB, Bigelow C, et al. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene 2009;28:4456-68.
12. Faibish M, Francescone R, Bentley B, Yan W, Shao R. A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers. Mol Cancer Ther 2011;10:742-51.
13. Ngemnyuang N, Francescone RA, Jearanaikoon P, Daduang J, Supoken A, Yan W, et al. Chitinase 3 like 1 is associated with tumor angiogenesis in cervical cancer. Int J Biochem Cell Biol 2014;51:45-52.
14. Li LL, Fan JT, Li DH, Liu Y. Effects of a small interfering RNA targeting YKL-40 gene on the proliferation and invasion of endometrial cancer HEC-1A cells. Int J Gynecol Cancer 2016;26:1190-5.
15. Xu CH, Yu LK, Hao KK. Serum YKL-40 level is associated with the chemotherapy response and prognosis of patients with small cell lung cancer. PLoS One 2014;9:e96384.
16. Lugowska I, Kowalska M, Fuksewicz M, Kotowicz B, Mierzejewska E, Kosela-Paterczyk H, et al. Serum markers in early-stage and locally advanced melanoma. Tumour Biol 2015;36:8277-85.
17. Høgdall EV, Ringsholt M, Høgdall CK, Christensen IJ, Johansen JS, Kjaer SK, et al. YKL-40 tissue expression and plasma levels in patients with ovarian cancer. BMC Cancer 2009;9:8.
18. Chen J, Liu X, Pan YQ, He BS, Ying HQ, Sun HL, et al. Analysis of diagnostic value of YKL-40 in ovarian cancer. Int J Gynecol Cancer 2016;
19. Zou L, Le X, Zhang JW. The efficacy of YKL-40 and CA125 as biomarkers for epithelial ovarian cancer. Braz J Med Biol Res 2010;43:1232-8.
20. Choudhuri S, Sharma C, Banerjee A, Kumar S, Kumar L, Singh N. A repertoire of biomarkers helps in detection and assessment of therapeutic response in epithelial ovarian cancer. Mol Cell Biochem 2014;386:259-69.
21. Dupont J, Tanwar MK, Thaler HT, Fleisher M, Kauf N, Hensley ML, et al. Early detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol 2004;22:3330-9.
22. Gronlund B, Høgdall EV, Christensen IJ, Johansen JS, Nørgaard-Pedersen B, Engolholm SA, et al. Pre-treatment prediction of chemoresistance in second-line chemotherapy of ovarian carcinoma: value of serological tumor marker determination (tetracinctin, YKL-40, CA125). Int J Biol Markers 2006;21:141-8.
23. Høgdall EV, Johansen JS, Kjaer SK, Price PA, Christensen L, Blaakaer J, et al. High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival. Oncol Rep 2003;10:1533-8.
24. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Int J Surg 2014;12:1495-9.
25. Pratt J, FIÇGO Committee on Gynecologic Oncology Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 2014;124:1-5.
26. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumors : revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:2248-7.
27. Sal V, Kahramanoğlu I, Bese T, Demirkiran F, Sofiyeva N, Soyman Z, et al. Is serum level of nestin useful in detecting epithelial ovarian cancer? J Int Gynaecol Obstet 2017;43:371-7.
28. Romagnolo C, Leon AE, Fabricio ASC, Taborelli M, Polesel J, Del Pup L, et al. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study. Gynecol Oncol 2016;141:303-11.
29. Yip P, Chen TH, Seshuah P, Stephen LL, Michael-Ballard KL, Mapes JP, et al. Comprehensive serum profiling for the discovery of epithelial ovarian cancer biomarkers. PLoS One 2011;6:e29533.
30. Chudecka-Glaz AM, Cymbaluk-Ploska AA, Menkiszaik JL, Sompolska-Rzechula AM, Tielczko-Grabarek AI, Rzeplka-Gorska IA. Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L, and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer. J Ovarian Res 2014;7:62.